March 30 - April 2, 2014
Hotel Galvez
Galveston, Texas

Lodging  |  Online Registration  |  Abstract Submission

Download program schedule »

The venue for the 6th International Symposium on Filoviruses is Galveston, Texas, USA. The Symposium will take place in the historic Hotel Galvez on the Gulf of Mexico. The hotel opened in 1911 and was named the Galvez in honor of Bernardo de Gálvez y Madrid, Count of Gálvez, for whom the city was also named.

The Symposium will cover all recent developments on Ebola and Marburg viruses, including the following topics:

- Virus Structure
- Virus Biology
- Pathology and Pathogenesis
- Vaccines
- Antivirals and Postexposure Treatments
- Virus Ecology
- Epidemiology
- Case Management and Diagnosis

The 6th International Symposium on Filoviruses is organized by Heinz Feldmann, Thomas Geisbert, and Yoshihiro Kawakita.

Online Registration

The registration fee is $625. Graduate students whose abstracts are selected will be offered a reduced rate. The symposium is now sold out.

Register online with a check or credit card »

If you are from UTMB and wish to use a UTMB account to pay the registration fee, please register here.

Cancellation Policy:

Full refunds less a $50 processing fee will be issued to registrants who cancel on or before February 15, 2014. Notification of cancellation should be emailed to Melissa Jones.

Hotel Information

Lodging is available at the Hotel Galvez, the site of the symposium. Lodging at the group rate is now sold out.

To register, call the hotel's direct line at 409-765-7721 and ask for reservations. Inform the reservationist that you are attending the UTMB Symposium on Filoviruses, which begins March 30, 2014, and would like to reserve a room at the group rate.

The group rate ($91 single occupancy/$112 double occupancy) is effective for the nights of Sunday, March 30, through Tuesday, April 1, 2014. If you plan to check in before March 30 or check out after April 2, you will need to reserve your room at the hotel's going rate for the other night(s).
If you have any questions or concerns regarding hotel registration, please email the symposium coordinator.

Ground Transportation Options

Free parking is available at the Hotel Galvez. Major car rental services are available at both airports:
  George Bush Intercontinental (IAH) Airport car rental services
  William P. Hobby (HOU) Airport car rental services

**Totally Texas Limousine Service** is offering UTMB’s discounted rate to those who make their reservation during 2013 and mention that they will be in town for the UTMB symposium.

**Galveston Limousine Service** offers low-cost trips from both airports according to their set schedule.

Directions from Houston Area Airports

- [Directions from Bush Intercontinental (IAH) to Hotel Galvez (70 Miles / 112 Kilometers)](#)
- [Directions from Hobby Airport (HOU) to Hotel Galvez (43 Miles / 69 Kilometers)](#)

Poster Dimensions

For poster presentations, the useable area of the display boards is 48”H x 72”W. We recommend that posters be 42”H x 56”W, although you may choose to present a slightly wider poster if you prefer (no wider than 66”, however).

George Ranch Historical Park

There will be an evening event and dinner on Tuesday, April 1, at the George Ranch Historical Park in Richmond, Texas. This is a 20,000 acre working ranch and guests will have an authentic Texas experience.

Buses will begin loading at the rear entrance of the Hotel Galvez along Avenue P around 4:00 p.m. and will depart promptly at 4:15 p.m. If you miss the buses, you can drive to the venue; directions can be found here. The trip to George Ranch will take a little over an hour. Please plan to bring casual attire for this event.
ACKNOWLEDGMENTS

The organizers of the 6th International Symposium on Filoviruses would like to express their sincere appreciation for the generous financial support from the following sponsors:

The McLaughlin Endowment

OTHER SUPPORTERS:

Integrated Biotherapeutics
Luminex
Microbiotix
6th International Symposium on Filoviruses

PROGRAM

March 30 (Sunday), 2014

18:45-21:45  Registration  Terrace Ballroom
18:45-21:45  Welcome Reception  Terrace Ballroom

March 31 (Monday), 2014

06:15-07:45  American-style Buffet Breakfast  Veranda
07:45-08:00  Opening Remarks  Music Hall

SESSION 1  VIRUS STRUCTURE & BIOLOGY 1  (Chairs: Y. Kawaoka, E. Muhlberger)  Music Hall

08:00-08:15  1S-1  Stefan Pöhmann  German Primate Center, Göttingen, Germany
MER, INTEGRIN αv AND NPC1 PROMOTE EBOLAVIRUS INFECTION OF MACROPHAGES

08:15-08:30  1S-2  Robert Davey  Texas Biomedical Research Institute, San Antonio, TX, USA
EARLY EVENTS IN EBOLAVIRUS INFECTION: EXOCYTOSIS BEFORE ENDOCYTOSIS

08:30-08:55  1S-3  Christopher Basler  Icahn School of Medicine at Mount Sinai, New York, NY, USA
MOLECULAR BASIS FOR MARBURG VIRUS VP24-KEAP1 INTERACTION AND ACTIVATION OF CYTOPROTECTIVE ANTIOXIDANT RESPONSES

08:55-09:20  1S-4  Victor Volchkov  CIRI INSERM U1111, Lyon, France
THE CELLULAR NRF2 DEPENDENT PATHWAY IS HIJACKED BY MARBURG VIRUS THROUGH INTERACTION OF THE VIRAL STRUCTURAL PROTEIN VP24 WITH NRF2-NEGATIVE REGULATOR KEAP1

09:20-09:35  1S-5  Judith White  University of Virginia, Charlottesville, VA, USA
MULTIPLE FDA-APPROVED COMPOUNDS BLOCK FILOVIRUS INFECTION THROUGH AN NPC1-DEPENDENT PATHWAY

09:35-09:50  1S-6  James Cunningham  Brigham and Women’s Hospital, Boston, MA, USA
MOLECULAR BASIS FOR RESISTANCE TO SMALL MOLECULE INHIBITOR OF EBOLA VIRUS INFECTION THAT TARGETS RECEPTOR NPC1

09:50-10:05  Coffee Break

10:05-10:30  1S-7  Erica O. Saphire  The Scripps Research Institute, La Jolla, CA, USA
THE FILOVIRUS SURFACE GLYCOPROTEIN: TRANSFORMATION, FUNCTION, AND IMMUNE DEFENSE

10:30-10:45  1S-8  Kartik Chandran  Albert Einstein College of Medicine, Bronx, NY, USA
NIEMANN-PICK C1: ROLES IN FILOVIRUS ENTRY, CELLULAR HOST RANGE, AND HOST-VIRUS EVOLUTIONARY ARMS RACES
10:45-11:00  1S-9  Peter Halfmann  
University of Wisconsin, Madison, WI, USA  
THE INVOLVEMENT OF HOST PROTEINS IN THE FORMATION OF EBOLA VIRUS INCLUSION BODIES

11:00-11:15  1S-10  Zachary Bornholdt  
The Scripps Research Institute, La Jolla, CA, USA  
STRUCTURAL REARRANGEMENT OF EBOLAVIRUS VP40 BEGETS MULTIPLE FUNCTIONS IN THE VIRUS LIFE CYCLE

11:15-11:30  1S-11  Thomas Hoenen  
NIAID, NIH, Hamilton, MT, USA  
A NOVEL LIFECYCLE MODELING SYSTEM FOR EBOLAVIRUSES SHOWS A GENOME LENGTH-DEPENDENT ROLE OF

11:30-14:10  Lunch Break & POSTER SESSION  (See poster set-up information on page 12)  
Veranda & Terrace  
Ballroom

SESSION 2  VIRUS ECOLOGY & EPIDEMIOLOGY  (Chairs: S. Nichol, J. Paweska)  
Music Hall

14:10-14:35  2S-1  Gary Kobinger  
Public Health Agency of Canada, Winnipeg, Manitoba, Canada  
TRANSMISSION OF EBOLA VIRUS IN GUINEA PIGS, PIGS AND PRIMATES

14:35-15:00  2S-2  Janusz Paweska  
National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, South Africa  
EXPERIMENTAL INFECTION OF ROUSETTUS AEGYPTIACUS WITH MARBURG VIRUS

15:00-15:20  2S-3  Jonathan Towner  
Centers for Disease Control and Prevention, Atlanta, GA, USA  
INVESTIGATIONS OF FIVOVIRUS REPLICATION IN WILD-CAUGHT AND CAPTIVE BRED ROUSETTUS AEGYPTIACUS

15:20-15:40  2S-4  Megan Jones  
University of Georgia, Athens, GA, USA  
PATHOLOGY OF EXPERIMENTAL MARBURG VIRUS INFECTION IN A NATURAL RESERVOIR HOST, THE EGYPTIAN FRUIT BAT (ROUSETTUS AEGYPTIACUS)

15:40-15:55  2S-5  Petrus Jansen van Vuren  
National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, South Africa  
SEROLOGICAL AND MOLECULAR EVIDENCE OF MARBURG VIRUS INFECTION AMONG ROUSETTUS AEGYPTIACUS IN SOUTH AFRICA

15:55-16:10  2S-6  Vincent Munster  
NIAID, NIH, Hamilton, MT, USA  
EBOLAVIRUS SEROPREVALENCE IN HAMMER-HEADED FRUIT BATS (HYPSIGNATHUS MONSTROSUS) IN THE REPUBLIC OF CONGO

16:10-16:25  2S-7  Barbara Knust  
Centers for Disease Control and Prevention, Atlanta, GA, USA  
MULTI-DISTRICT OUTBREAK OF MARBURG HEMORRHAGIC FEVER, UGANDA, OCTOBER-NOVEMBER 2012

16:25-16:45  Coffee Break
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45-17:45</td>
<td>SESSION 3</td>
<td>KEYNOTE ADDRESS</td>
<td>W. Ian Lipkin</td>
<td>Music Hall</td>
</tr>
<tr>
<td>18:30~</td>
<td></td>
<td>Gala Dinner</td>
<td></td>
<td>Veranda</td>
</tr>
<tr>
<td>06:15-07:45</td>
<td>06:15-07:45</td>
<td>American-style Buffet Breakfast</td>
<td></td>
<td>Veranda</td>
</tr>
<tr>
<td>07:45-08:00</td>
<td>SPECIAL SESSION</td>
<td>LATE BREAKER TALK</td>
<td>TBD</td>
<td>Music Hall</td>
</tr>
<tr>
<td>08:00-08:15</td>
<td>SESSION 4</td>
<td>PROPHYLAXIS &amp; THERAPY 1 (Chairs: H. Feldmann, G. Kobinger)</td>
<td>Gene Olinger</td>
<td>Music Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEVELOPMENT OF A MONOCLONAL ANTIBODY COCKTAIL FOR EBOLA VIRUS THERAPY</td>
<td>Integrated Research Facility, NIH, Frederick, MD, USA</td>
<td></td>
</tr>
<tr>
<td>08:15-08:30</td>
<td></td>
<td>rVSV VECTORED TRI-VALENT FILOVIRUS VACCINE</td>
<td>John Eldridge</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>rVSV FILOVIRUS VACCINES: SAFETY, DURABILITY, AND NEW FRONTIERS IN FILOVIRUS CROSS-PROTECTION</td>
<td>Profectus BioSciences, Inc., Baltimore, MD, USA</td>
<td></td>
</tr>
<tr>
<td>08:30-08:45</td>
<td></td>
<td>rVSV FILOVIRUS VACCINES: SAFETY, DURABILITY, AND NEW FRONTIERS IN FILOVIRUS CROSS-PROTECTION</td>
<td>Chad Mire</td>
<td></td>
</tr>
<tr>
<td>08:45-09:10</td>
<td></td>
<td>T CELL CORRELATES OF DURABLE PROTECTION AGAINST LETHAL EBOLAVIRUS CHALLENGE</td>
<td>Annie Lau-Kilby</td>
<td></td>
</tr>
<tr>
<td>09:10-09:25</td>
<td></td>
<td>FILOVIRUS SURVIVORS IN UGANDA: HUMAN MONOCLONAL ANTIBODY DEVELOPMENT AND PROFILING IMMUNE STATUS</td>
<td>John Dye, Jr.</td>
<td></td>
</tr>
<tr>
<td>09:25-09:40</td>
<td></td>
<td>DEVELOPMENT OF LIPID NANO-PARTICLE RNAI THERAPEUTICS AGAINST EBOLA AND MARBURG HEMORRHAGIC FEVER VIRUSES</td>
<td>Ian MacLachlan</td>
<td></td>
</tr>
<tr>
<td>09:40-09:55</td>
<td></td>
<td>MUCIN-DELETED FILOVIRUS GLYCOPROTEINS AS VACCINES AND IMMUNOGENS FOR PAN-FILOVIRUS ANTIBODY DEVELOPMENT</td>
<td>Kelly Warfield</td>
<td></td>
</tr>
</tbody>
</table>
09:55-10:10 4S-8 Xiangguo Qiu
Public Health Agency of Canada, Winnipeg, Manitoba, Canada
THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST EBOLA VIRUS INFECTION

10:10-10:25 Coffee Break

SESSION 5 PATHOLOGY & PATHOGENESIS
(Chairs: P. Rollin, V. Volchkov) Music Hall

10:25-10:50 5S-1 Alexander Bukreyev
University of Texas Medical Branch, Galveston, TX, USA
THE LACK OF MATURATION OF FILOVIRUS-INFECTED DENDRITIC CELLS: THE ROLE OF INDIVIDUAL VIRAL PROTEINS AND EFFECTS ON T CELL RESPONSES

10:50:11:05 5S-2 Andrea Marzi
NIAD, NIH, Hamilton, MT, USA
MARBURG HEMORRHAGIC FEVER IN A SYRIAN GOLDEN HAMSTER MODEL

11:05-11:20 5S-3 Anita McElroy
Centers for Disease Control and Prevention, Atlanta, GA, USA
EBOLA HEMORRHAGIC FEVER IN CHILDREN

11:20-11:35 5S-4 Robert Cross
University of Texas Medical Branch, Galveston, TX, USA
COMPARATIVE PATHOGENESIS OF MARBURG VIRUS DISEASE BETWEEN ANGOLA AND RAVN STRAINS IN THE OUTBRED GUINEA PIG

11:35-13:00 Lunch Break Veranda

SESSION 6 VIRUS STRUCTURE & BIOLOGY 2
(Chairs: S. Becker, E. Saphire) Music Hall

13:00-13:25 6S-1 Elke Mühlberger
Boston University, Boston, MA, USA
HOW TO AVOID STRESS - SEQUESTRATION OF STRESS GRANULE PROTEINS IN EBOLA VIRUS INCLUSIONS

Institut für Virologie, Philipps-University, Marburg, Germany
TRANSPORT AND ASSEMBLY OF MARBURG VIRUS NUCLEOCAPSIDS

13:50-14:05 6S-3 Laure Deflube
Boston University, Boston, MA, USA
THE EBOLAVIRUS REPLICATION INITIATION MECHANISM IS UNIQUE AMONG MONONEGAVIRIDAE

14:05-14:20 6S-4 Gaya Amarasinghe
Washington University School of Medicine, St. Louis, MO, USA
MULTIFUNCTIONAL FILOVIRAL VP35 PROTEINS AS THERAPEUTIC TARGETS

14:20-14:30 Coffee Break

14:30-14:45 6S-5 Logan Banadyga
NIAD, NIH, Hamilton, MT, USA
THE DETERMINANTS OF THE NP24-NP INTERACTION AND ITS CRITICAL ROLE IN THE REGULATION OF EBOLA VIRUS TRANSCRIPTION/REPLICATION

14:45-15:00 6S-6 Olga Dolnik
Institut für Virologie, Philipps-University, Marburg, Germany
EMERGING FUNCTIONS OF TSG101 IN MARBURG VIRUS INFECTION.
EMERGING FUNCTIONS OF TSG101 IN MARBURG VIRUS INFECTION.

AUTOPHAGY CONTROLS INTERNALIZATION OF EBOLAVIRUS INTO HOST CELLS

STRUCTURE AND INHIBITION OF MEMBRANE FUSION INTERMEDIATES IN FILOVIRUS GLYCOPROTEIN-MEDIATED CELL ENTRY

**April 2 (Wednesday), 2014**

06:15-07:45 **American-style Buffet Breakfast** Veranda

**SESSION 7 PROPHYLAXIS & THERAPY 2** (Chairs: T. Geisbert, N. Sullivan) Music Hall

07:45-08:00 7S-1 **William Sheridan** BioCryst Pharmaceuticals, Durham, NC, USA

NOVEL BROAD-SPECTRUM NUCLEOSIDE ANALOGUE, BCX4430, PROTECTS AGAINST FILOVIRUS INFECTIONS IN ANIMAL MODELS

08:00-08:15 7S-2 **Mark Lever** Biomedical Sciences,Dstl Porton Down, Salisbury, United Kingdom

POST-EXPOSURE THERAPY OF EXPERIMENTAL FILOVIRUS INFECTION IN THE MOUSE AND NHP (MARMOSET)

08:15-08:40 7S-3 **Ayato Takada** Hokkaido University, Sapporo, Japan

ROLE OF ANTIBODIES IN PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION

08:40-08:55 7S-4 **Connie Schmaljohn** United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, USA

CODON-OPTIMIZED FILOVIRUS DNA VACCINES DELIVERED BY INTRAMUSCULAR ELECTROPORATION PROTECT CYNOGLOSSUS MACAQUES FROM LETHAL EBOLA AND MARBURG VIRUS CHALLENGES

08:55:09:10 7S-5 **Charles D. Murin** The Scripps Research Institute, La Jolla, CA, USA

WHY IS 13C6 EFFECTIVE AGAINST EBOLA VIRUS INFECTION?

09:10-09:25 7S-6 **Michelle Meyer** University of Texas Medical Branch, Galveston, TX, USA

AEROSOL VACCINATION AGAINST EBOLA VIRUS

09:25-09:40 7S-7 **Gary Wong** University of Manitoba, Winnipeg, Canada

IMMUNIZATION WITH VESICULAR STOMATITIS VIRUS VACCINE EXPRESSING EBOLA GP PROVIDES SUSTAINED LONG-TERM PROTECTION TO EBOLA VIRUS CHALLENGE IN RODENTS
09:40-09:55 7S-8 Matthias Schnell
Thomas Jefferson University, Philadelphia, PA, USA
PRECLINICAL DEVELOPMENT OF KILLED RABIES VIRUS BASED TETRAVALENT VACCINE AGAINST RABIES AND FILOVIRUSES

09:55-10:10 Coffee Break

SESSION 8
FILOVIRUS LABORATORY AND FIELD EXPOSURES
(Chairs: L. Hensley, P. Jahrling)

10:10-11:45 8S-1 SESSION 8
POST EXPOSURE INTERVENTION FOLLOWING POTENTIAL EXPOSURES IN THE LABORATORY OR THE FIELD: LESSONS LEARNED AND STEPS FOR THE FUTURE

10:10-10:30 Lisa Hensley
 Integrated Research Facility, NIAID, NIH, Bethesda, MD, USA
INTRODUCTION AND REVIEW OF COUNTER-MEASURES

10:30-10:40 Alexander Bukreyev
University of Texas Medical Branch, Galveston, TX, USA
LESSONS LEARNED FROM PAST LABORATORY EXPOSURES (I)

10:40-10:50 Hans-Dieter Klenk
Institut für Virologie, Philipps-University, Marburg, Germany
LESSONS LEARNED FROM PAST LABORATORY EXPOSURES (II)

10:50-11:00 Armand Sprecher
Medecins Sans Frontieres - Operational Centre Brussels, Brussels, Belgium
MANAGING POTENTIAL FIELD EXPOSURES (I)

11:00-11:20 Gary Kobinger
Public Health Agency of Canada, Winnipeg, Manitoba, Canada
MANAGING POTENTIAL FIELD EXPOSURES (II)

11:20-11:30 Peter Jahrling
Integrated Research Facility, NIAID, NIH, Bethesda, MD, USA
NEXT STEPS: ARE WE ANY BETTER PREPARED NOW THAN WE WERE 10 YEARS AGO?

11:30-11:45 Round Table
PANEL DISCUSSION

11:45-13:15 Lunch Break

SESSION 9
VIRUS BIOLOGY & PATHOGENESIS
(Chairs: C. Basler, A. Marzi)

13:15-13:30 9S-1 Angela Rasmussen
University of Washington, Seattle, WA, USA
DEVELOPMENT OF A MOUSE MODEL OF EBO-LA HEMORRHAGIC FEVER IN THE COLLABORATIVE CROSS, A SYSTEMS GENETICS RESOURCE
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>University</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:45</td>
<td>9S-2</td>
<td>Chinglai Yang</td>
<td>Emory University, Atlanta, GA, USA</td>
<td>IMMUNE SUBVERSION BY SGP: IMPLICATIONS FOR EBOLAVIRUS VACCINE DEVELOPMENT</td>
</tr>
<tr>
<td>13:45-14:10</td>
<td>9S-3</td>
<td>Hideki Ebihara</td>
<td>NIAID, NIH, Hamilton, MT, USA</td>
<td>FILOVIRUS PROTEIN FUNCTIONS LINKED TO PATHOGENESIS</td>
</tr>
<tr>
<td>14:10-14:25</td>
<td>9S-4</td>
<td>Ronald Harty</td>
<td>University of Pennsylvania, Philadelphia, PA, USA</td>
<td>SMALL MOLECULE COMPOUNDS TARGETING FILOVIRUS L-DOMAIN/HOST INTERACTIONS BLOCK EGRESS</td>
</tr>
<tr>
<td>14:25-14:40</td>
<td>9S-5</td>
<td>John Connor</td>
<td>Boston University, Boston, MA, USA</td>
<td>TRANSCRIPTIONAL PROFILING OF THE IMMUNE RESPONSE TO MARBURG INFECITON</td>
</tr>
<tr>
<td>14:40-14:55</td>
<td>9S-6</td>
<td>Jason Kindrachuk</td>
<td>NIAID, NIH, Bethesda, MD, USA</td>
<td>TEMPORAL KINOME ANALYSIS DEMONSTRATES EBOLA VIRUS SELECTIVELY MODULATES TRANSFORMING GROWTH FACTOR BETA SIGNALING</td>
</tr>
<tr>
<td>14:55-15:05</td>
<td>9S-7</td>
<td>Wendy Maury</td>
<td>University of Iowa, Iowa City, IA, USA</td>
<td>CHARACTERIZATION OF THE ROLES OF N-LINKED GLYCANS ON EBOLA VIRUS GLYCO PROTEIN</td>
</tr>
<tr>
<td>15:05-15:15</td>
<td></td>
<td>Concluding Remarks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>